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JOHN A. AMBROSE, MD, FACC
New York, New York
In patients with mitral stenosis, valveorificecalculations
using pulmonary capillary wedgepressure as a substitute
for left atrial pressure may overestimate the severity of
disease. Previous studies have shown that mitral valve
area determined from transseptal left atrial pressure
measurements exceeds that area derived from pulmo-
nary wedge pressure measurements. This is probably
due to pulmonary venoconstriction, which is reversed
by nitroglycerin. Nitroglycerin, 0.4 mg, was adminis-
tered sublingually to 20 patients with mitral valvedisease
during preoperative cardiac catheterization using the
pulmonary capillary wedge pressure as the proximal hy-
draulic variable. At the time of peak hypotensive effect,
3 to 5 minutes after nitroglycerin administration, the
mean pulmonary capillary wedgepressure decreasedfrom
23 ± 2 (mean ± SEM) to 19 ± 2 mm Hg (p < 0.005).
The mean diastolic transmitral pressure gradient (12.6
± 1.2 mm Hg before and 11.5 ± 1.0 mm Hg after
Application of hydraulic formulas to the determination of
the severity of mitral stenosis depends on the faithfulness
with which left atrial pressure is reflected in the pulmonary
capillary wedge pressure. Under certain circumstances of
pulmonary hypertension, pulmonary venoconstriction can
increase the pulmonary wedge pressure above left atrial
pressure, leading to overestimation of the severity of mitral
valve obstruction (I). Discrepancies of this sort have been
From the Cardiothoracic Center, Mount Sinai Medical Center, New
York. New York. This study was presented in part at the 35th Annual
Scientific Session of the American College of Cardiology, Atlanta, Geor-
gia, March 1986.
Manuscript received October 27, 1986; revised manuscript received
January 14, 1987, accepted February 4, 1987.
Address for reprints: Jonathan L. Halperin, MD, Division of Cardiol-
ogy, Mount Sinai Medical Center, Fifth Avenue at lOOth Street, New
York, New York 10029.
© J987 by the American College of Cardiology
nitroglycerin; p = NS) and cardiac output (4.0 ± 0.3
to 4.1 ± 0.3 liters/min; p = NS) did not change signif-
icantly. Nevertheless, the hemodynamic mitral orifice
area, calculatedusing the Gorlin formula, increased from
0.8 ± 0.1 to 1.1 ± 0.2 cm2 (p < 0.05). In 12 patients
with isolated mitral stenosis, without regurgitation, the
mitral valve orifice area after nitroglycerin was 0.4 ±
0.2 em! larger than it was before drug administration
(p < 0.05).
Administration of nitroglycerin during evaluation of
mitral stenosis eliminates pulmonary venoconstriction,
which raises the pulmonary capillary wedge pressure
above the left atrial pressure in some patients. Nitro-
glycerin may add diagnostic accuracy without transsep-
tal catheterization. Whether this response to nitroglyc-
erin has direct therapeutic value in patients with mitral
valve obstruction has yet to be determined.
(J Am Coll CardioI1987;10:342-8)
reported (2) to produce errors ranging up to 27 mm Hg in
mitral valve pressure gradient determinations and errors up
to 1.5 ern" in mitral orifice area calculations although dif-
ferences are usually much smaller. To avoid this source of
error, direct left atrial catheterization is employed in some
laboratories using methods such as the trans septal puncture
technique, but these are relatively difficult and sometimes
dangerous (3). We have recently demonstrated in postop-
erative patients (4) that sublingual administration of nitro-
glycerin produces prompt dilation of the pulmonary veins
or microcirculation, reducing the pulmonary venous gra-
dient, which can spuriously separate pulmonary wedge and
left atrial pressures. The present study was undertaken to
determine whether the improved agreement between pul-
monary wedge and left atrial pressures produced by nitro-
glycerin might have significant hemodynamic impact on
effective orifice and flow characteristics during diagnostic
cardiac catheterization in patients with a clinical diagnosis
of mitral stenosis.
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Methods
Study patients (Table 1). Twenty patients with clinical
and echocardiographic features of mitral valve disease were
studied during preoperative cardiac catheterization . In-
formed consent was obtained from each patient in accord-
ance with institutional guidelines. There were 4 men and
16 women , ranging in age from 26 to 74 years (average 50
± 4) . Mitral stenosis was accompanied by cineangiographic
evidence of mitral regurgitation in five cases; there was
associated aortic valve disease in nine and tricuspid disease
in two . In 12 patients, mitral stenosis was not accompanied
by a significant regurgitant valvular lesion, and results in
these cases were subjected to supplementary analysis. Eight
patients had sinus cardiac rhythm and 12 had atrial fibril-
lation .
Instrumentation and measurements. A transvenous 7F
Swan-Ganz catheter was positioned in a pulmonary artery
segment in each case and pulmonary capiIlary wedge pres-
sure was verified by examination of pulse wave configu-
ration and by oximetry of blood sampled through the oc-
cluding catheter. A 7F catheter was also positioned in the
left ventricular cavity for measurement of systolic and di-
astolic pressures. Both left and right heart pressures were
measured using fluid-filled catheters connected to equi-
sensitive Statham P23Db transducers that were independently
calibrated against a mercury column with the zero reference
at the level of the midaxillary line. Pressure waveforms and
a simultaneous electrocardiographic (ECG) signal were dis-
played and recorded on an Electronics for Medicine multi-
channel photographic recorder before and after reversal of
the transducers to minimize the systematic error of mea-
surement. The left ventricular catheter was employed for
measurement of systolic blood pressure except in Patient 8
(with associated aortic stenosis) in whom direct proximal
aortic pressure was measured.
The mean pulmonary artery and mean pulmonary cap-
illary wedge pressures were determined by electronic in-
tegration of phasic signals . The diastolic transmitral pressure
gradient was determined by planimetry of waveform tran-
scriptions throughout the diastolic filling period over 10
consecutive beats during cyclic respiration, after transposing
the pressure tracings to correct for phase delay. Transmitral
blood flow was estimated by right heart thermodilution tech-
nique, using an American Edwards Laboratories model 9520A
cardiac output computer, averaging at least three replicate
determinations differing by < 10%.
Hemodynamic formulas. Mitral valve orifice was cal-
culated according to the formula :
MVA = (MVF/38 YMVG),
where MYA = mitral valve area in ern", MYF = mitral
flow determined by dividing the diastolic fiIling period in
seconds/min into cardiac output in mllmin and MYG
mean mitral diastolic gradient in mm Hg.
The total pulmonary vascular resistance (TPR) in
dynes-s-cm - 5 was calculated as
TPR = (PA x 80/CO),
Table 1. Clinical Characteristics of the 20 Patients
Patient
No.
Age (yr)
&Sex Diagnosis Rhythm MR
1 4lF MS AF 0
2 SSM MS. TVD AF 0
3 73M MS, MR SR 1+
4 65F MS. AVD AF 0
5 74F MS AF 0
6 37F MS. AVD SR 0
7 48F MS, AVD AF 0
8 31F MS, AVD SR 0
9 36F MS, MR AF 4 +
10 44F MS AF 0
It 28M MS. AVD SR 0
12 50F MS. MR SR 2+
13 56M MS, TVD . AVD AF 0
14 67F MS. MR. AVD AF 3+
15 74F MS, MR, AVD AF 2+
t6 26F MS SR 0
17 58F MS. AVD AF 0
18 37F MS AF 0
19 61F MS SR 0
20 42M MS SR 0
AF = atrial fibrillation; AVD = aortic valve disease : F = female: M = male: MR = mitral regurgitation
(graded 0 to 4+): MS = mitral stenosis: SR = sinus rhythm: TVD = tricuspid valve disease.
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where PA = mean pulmonary artery pressure in mm Hg
and CO = cardiac output in liters/min.
Pulmonary "arteriolar' resistance (PAR) in dynes-s-cm- 5
was defined as
PAR = [(PA - PW)80/COj,
where PW = the mean pulmonary capillary wedge pressure
in mm Hg (5).
Drug intervention. Cardiovascular medications were
withheld in each case for at least 8 hours before hemody-
namic study in the laboratory. Stable baseline hemodynamic
status was verified by repeated measurements over 20 min-
utes. Each patient was then given nitroglycerin, 0.4 mg
sublingually, and measurements of pressure and flow were
repeated within the time of peak systemic hypotensive ef-
feet. This dose of nitroglycerin was repeated 5 to 10minutes
later when mean arterial pressure did not decrease at least
5 mm Hg after the first dose.
Statistics. Results were expressed as the mean ± SEM
for measured and derived data in all patients and in those
with isolated mitral stenosis. Drug-induced changes were
evaluated by the Student's t test for paired variables. Sig-
nificance was accepted at a confidence level of 95% (p ~
0.05).
Results
Hemodynamics. Hemodynamic data obtained at base-
line and during the peak systemic hypotensive effect of
sublingual nitroglycerin are displayed for each patient in
Table 2. Systolic left ventricular pressure was normal in
most of these cases before intervention, but moderate pul-
monary artery hypertension was generally present. The pul-
monary capillary wedge pressure was elevated, but the left
ventricular end-diastolic pressure was within the normal
range in these patients with predominant mitral stenosis.
Valvular obstruction was, on average, moderately severe,
with valve areas in the range of 0.8 crrr' . This constitutes
an essentially minimal estimate in patients with associated
valvular regurgitation.
Systolic left ventricular/arterial blood pressure decreased
with nitroglycerin administration from 127 ± 5 to 118 ±
5 mm Hg (p < 0.005). Cardiac output was preserved (4.0
± 0.3 liters/min before and 4.1 ± 0.3 liters/min after
nitroglycerin (p = NS) and there was a slight increase in
heart rate (80 ± 4 to 84 ± 4 beats/min; p < 0.005). The
stroke volume index, however, did not increase (31 ± 2 to
30 ± 2 ml/beat per nr': p = NS).
The mean pulmonary capillary wedge pressure decreased
from 23 ± 2 to 19 ± 2 mm Hg (p < 0.005) after nitro-
glycerin, whereas the left ventricular end-diastolic pressure
decreased from 8 ± I to 6 ± I mm Hg (p < 0.005; Fig.
I). The mean pulmonary artery pressure decreased from 33
± 3 to 29 ± 3 mm Hg (p < 0.005) as a result of drug
intervention. The total pulmonary resistance decreased from
685 ± 69 dynes-s-cm- 5 before to 653 ± 65 dynes-s-cm - 5
after nitroglycerin (p < 0.005) , whereas pulmonary "ar-
teriolar" resistance was 262 ± 54 dynes-s-cm- 5 before and
213 ± 31 dynes-s-cm- 5 after pharmacologic intervention
(p = NS).
Mitral valve pressure gradient and calculated valve
area. The mean diastolic transrnitral pressure gradient de-
creased from 12.6 ± 1.2 to 11.5 ± 1.0 mm Hg (p = NS)
after nitroglycerin administration. It decreased in II of the
total group of 20 patients and in 8 of the 12 patients with
isolated mitral stenosis. The relation among mitral flow,
gradient and area is displayed in Figure 2. Representative
hemodynamic recordings from one patient with pure mitral
stenosis (Case 10) before and after administration of sub-
lingual nitroglycerinare presented in Figure 3. For the group
as a whole the calculated effective mitral orifice area in-
creased from 0.8 ± 0.1 to 1.1 ± 0.2 ern" (p < 0.05) after
nitroglycerin administration, and the average increase was
10%. In patients with mitral stenosis and no mitral regur-
gitation, the calculated mitral valve area increased an av-
erage of 0.4 ± 0.2 crrr ' after nitroglycerin, but in some
patients with severe stenosis there was no increase (Fig. 4).
Discussion
Pulmonary wedge-left atrial pressure relation. In the
35 years since Hellems et al. (6) first described human
pulmonary capillary wedge pressure, numerous investiga-
tors have reported a close correlation between this pressure
and directly measured left atrial pressure. As a consequence,
pulmonary wedge pressure measurements have become the
standard method of estimating left atrial pressure in most
cardiac catheterization laboratories. It has long been appre-
ciated, however, that this correlation is occasionally faulty.
Luchsingeret al. (7) found pulmonary capillary wedge pres-
sure on average to be 35% higher than mean left atrial
pressure. In patients with mitral valve disease, several in-
vestigators (8,9) measured pulmonary capillary wedge pres-
sure simultaneously with left atrial pressure and found dif-
ferences ranging from negligible values to nearly II mm
Hg, but more often in the range of 5 to 7 mm Hg. When
the pulmonary capillary wedge pressure exceeded 10 mm
Hg, considerable variation between these values was ob-
served in patients undergoing diagnostic cardiac catheter-
ization (10).
More recently, it has been demonstrated (II) that al-
though mean pulmonary capillary wedge pressure closely
approximates mean left atrial pressure over a wide range,
important overestimation of the mitral valve gradient may
occur in patients with mitral valve disease and this discrep-
ancy has been attributed to the less rapid y descent of phasic
pulmonary wedge pressure than of left atrial pressure pulse
form. Hence, although the pulmonary capillary wedge pres-
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Patient
No.
2
3
4
5
6
7
10
II
12
14
15
16
17
18
I')
20
Mean
±SEM
p Value
Nitroglycerin
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
Before
After
PW
25
19
27
24
14
II
I')
18
26
22
33
24
23
20
17
10
20
24
30
28
10
10
28
27
30
21
II
8
19
17
32
23
± 2
19
± 2
<0.005
LVEDP
16
')
13
6
')
8
7
4
5
7
II
')
3
3
12
5
8
6
3
3
')
9
14
7
5
5
8
')
9
9
6
2
15
13
')
6
2
D
4
I
8
± 10
6
± 1.0
<0.005
PA
34
35
40
34
18
14
35
27
.15
.12
45
35
28
26
38
38
18
15
36
2')
27
15
14
11
24
65
50
33
± 3
2')
:+: .1
<0.005
SAP
128
12.1
147
14')
100
85
13')
116
123
106
128
121
160
136
140
140
100
100
121
U2
100
')3
120
100
')5
104
114
126
183
176
IDS
108
142
123
119
103
ISO
126
117
108
127
118
.+ 5
<0.005
HR
78
78
6')
72
72
72
78
78
72
84
96
108
124
126
80
84
78
78
102
102
66
60
71
77
84
84
78
72
78
84
90
108
48
54
54
60
78
')0
108
114
80
± 4
84
4, 4
<0.005
co
4.5
4.7
3.7
3.7
3.1
3.X
3.0
2.3
2.4
2.1
69
6.3
3.2
3.1
6.0
7.4
4.2
5.2
4.3
39
4.5
4.3
.17
.18
3.')
3.')
I.')
I.')
27
2.')
5.8
5.8
2.7
3.2
4.5
48
1')
3.8
59
4.7
4.0
± 03
4.1
± 0.3
NS
MVG
11.4
107
133
13.7
17.1
15')
5.4
5.9
105
8.2
12.5
9.4
2D
18.')
9.4
11.8
13.5
U.7
180
6.1
12.0
14.7
11.6
ID.I
18.7
14.8
2.7
2.')
1lJ.5
13.3
18.4
18.5
7.5
10.6
4.3
3.4
129
IU
\').9
155
12.6
± 1.2
11.5
+ 10
NS
MVA
1.21
1.24
0.58
0.64
0.41
0.46
0.67
063
0.42
033
0.98
1.40
0.46
D.45
2.ID
39D
D.95
1.00
D.93
3.40
0.91
0.71
I.D8
UO
0.55
0.59
0.57
0.59
0.43
0.45
OlQ
0.90
055
D.42
1.70
2.10
D.M
1.10
I.DO
0.82
0.8
± 0.1
1.1
± 0.2
«J.D5
SVI
29
30
36
34
25
3D
27
20
23
17
38
31
15
15
47
55
30
38
30
27
38
40
27
26
26
26
17
19
24
24
41
34
40
42
51
49
29
25
33
25
31
± 2
30
:+: 2
NS
TpR
604
596
865
735
48D
487
1.167
1,029
406
406
1.125
903
.173
562
779
77')
758
632
497
85')
675
267
233
656
505
881
851
685
± 6')
653
± 65
<0.005
PAR
195
350
335
211
107
ID4
533
343
720
127
300
335
67
43
1M
205
337
211
83
71
100
267
147
447
262
± 54
213
± 31
NS
co = cardiac output (Iiters/rnin): HR = heart rate (beats/min); LVEDp = left ventricular end-diastolic pressure (rnm Hg): MVA = mitral valve
orifice area (em"): MVG = mean diastolic transrnitral pressure gradient (rnm Hg): pA = mean pulmonary artery pressure (rnrn Hg); PAR = pulmonary
arteriolar resistance (dynes-s-cm 5); PW = mean pulmonary capillary wedge pressure (mm llg): SAP = systolic left ventricular/arterial pressure (rnm
Hg); SVI = stroke volume index (rnl/beat per m'); TpR = total pulmonary resistance (dynes-s-cm 5).
sure has been used as a substitute for left atrial pressure
measurement to determine mitral valve orifice area in pa-
tients with mitral stenosis, the possible inequality of these
readings could be a source of clinically important error.
Schoenfeld et a!. (12) compared estimates of mitral
hemodynamics using pulmonary capillary wedge pressure
and direct transseptal catheterization of the left atrium in
patients with a prosthetic mitral valve and symptoms of
congestive heart failure. The diastolic gradient across the
prosthetic valve was overestimated when pulmonary wedge
rather than direct left atrial pressure measurement was used.
and the calculated mitral valve prosthetic orifice area was
underestimated by the pulmonary wedge determination. These
findings were attributed either to the phase delay of the
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Figure 3. Simultaneous pulmonary wedge (PW) and left ventric-
ular (LV) pressure waveform recordings obtained from one patient
before and after nitroglycerin administration. Despite the modest
decline in mitral flow in this case, the effective valve area increased
from 0.9 to 3.4 crrr'. EKG = electrocardiogram.
Before After
NITROGLYCERIN
pulmonary wedge V waves relative to the atrial V waves,
resulting in higher indirect estimates of mean diastolic left
atrial pressure, or to faulty wedge determinations in the
setting of pulmonary hypertension. In our study, left atrial
pressure was not measured directly, and comparison with
results obtained by transseptal, transbronchial or retrograde
transmitral catheterization of the atrium must be made cau-
tiously. The results of both studies (the present one and that
Figure I. Mean pulmonary capillary wedge pressure and left ven-
tricular end-diastolic pressure in 20 patients with mitral valve dis-
ease at cardiac catheterization, before and after administration of
sublingual nitroglycerin (mean ± SEM).
Figure 2. Calculated effective mitral valve area, mean diastolic
pulmonary wedge-left ventricular pressure gradient (determined
by graphic planimetry) and cardiac output before and after nitro-
glycerin in 20 patients with mitral valve disease (mean ± SEM).
14,-----------,
Figure 4. Effective mitral valve area in each of 12 patients with
mitral stenosis and no mitral regurgitation, before and after nitro-
glycerin. In several patients with severe stenosis there was no
change in calculated valve orifice, but substantial changes occurred
in patients with less severe disease.
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of Schoenfeld et al. [12J) nevertheless supportthecontention
that mitral area calculations based on pulmonary capillary
wedgepressure readings in the absenceof nitroglycerin may
underestimate the hemodynamic area. The actual mechan-
ical valve orifice, however, has eluded precise direct mea-
surement even in surgicalcases of rheumatic mitralstenosis.
Pulmonary venous hemodynamics. We have previ-
ously demonstrated (4), in patients after mitral valve re-
placementsurgery, that the pulmonary capillary wedgepres-
sure mayexceedleft atrial pressure and that this discrepancy
is due to reversible constriction of the pulmonary veins or
microcirculation, which is reversed by nitroglycerin. In an-
imal studies conducted over two decades ago (13), the de-
crease in pressure between the pulmonary venules and left
atriumwas shown to accountfor up to half the total gradient
between the pulmonary artery and left atrium. In our pre-
vious work (4), nitroglycerin administered sublingually
produced prompt pulmonary venodilation. reduced the pul-
monary venous gradient and brought the pulmonary capil-
lary wedge pressure into closer agreement with left atrial
pressure. It was this observation that formed the basis for
the present investigation.
Action of nitroglycerin. The vasodilator effects of ni-
troglycerin, although more pronounced on peripheral veins,
nevertheless result in lowering of left ventricularfilling pres-
sure by reducing both venous return and peripheral resist-
ance. However. Mookherjee et al. (14) noted that nitro-
glycerin produces pulmonary vasodilation even when cardiac
output andsystemic vascularresistanceare unchanged. Hence,
pulmonary artery pressure and pulmonary capillary wedge
pressure decrease after administration of nitroglycerin in
patients with congestive heart failure as a result of a decrease
in both left atrial pressure and aortic impedance to left ven-
tricular ejection. Direct pulmonary arteriolar dilation may
also be contributory, and the use of nitroglycerin has been
advocated in patients with severe pulmonary hypertension
(15) .
Clinical implications. Clinical application of hydraul ic
formulas, such as that devised by Gorlin and Gorlin (16).
to the determination of the severity of mitral stenosis de-
pends in large part on the faithfulness with which left atrial
pressure is reflected in the pulmonary capillary wedge pres-
sure. Pulmonary venoconstriction in cases of pulmonary
hypertension could increase the regional resistance to blood
flow independent of arteriolaror atrial tone, leading to over-
estimation of the severity of mitral stenosis as reported by
several investigators. This method presumes a single level
of stenosis, namely, that at the mitralorifice. Because avail-
able data suggest an additional level of disequil ibrium be-
tween pulmonary capillary wedge pressure and left heart
diastolic pressure at the level of the pulmonary veins or
microcirculation, calculations based on pulmonary capillary
wedge pressure measurements may give rise to potentially
large errors in mitral gradient estimations and underesti-
mation of mitral valve areas by as much as 1.5 em".
The results of this study suggest that the administration
of nitroglycerin during the evaluationof mitral stenosis less-
ens the pulmonary venoconstrictionwhich raises pulmonary
wedge pressure above left atrial pressure in some patients.
Nitroglycerin produces changes in estimated proximal (pul-
monary wedge/left atrial) pressure, diastolic gradient and
effective valve area, which are analogous to those obtained
duringdirect left atrialcatheterizationusing transseptal tech-
nique. It might be argued, therefore. that administration of
sublingual nitroglycerin should be incorporated in the rou-
tine hemodynamicevaluation of patients with suspected mi-
tral valve disease, and might avoid the occasional need for
transseptal puncture, because the latter technique carries the
risk of aortic perforation and intrathoracic hemorrhage (17).
Lowering of pulmonary artery and pulmonarycapillary wedge
pressures while preserving cardiac output may also have
direct therapeutic value in some patients with this form of
valvular heart disease. Whether clinical benefitaccrues from
such intervention, however. remains to be determined from
placebo-controlled trials.
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